Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
anti-CD19/BCMA U CAR T cells in Relapsed/Refractory Immune-mediated Kidney Disease
NCT07241468Phase 1Recruiting
- Sponsor
- Changhai Hospital
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KN3601 in Immune-Mediated Kidney Disease, membranous nephropathy (MN), IgA nephropathy (IgAN) and 1 more, sponsored by Changhai Hospital. Primary endpoints: Incidence of Dose-Limiting Toxicity up to 52 weeks and Incidence of Treatment Emergent Adverse Events up to 52 weeks. Started Nov 2025; status: recruiting.
02
Drugs
KN3601
03
Conditions
Immune-Mediated Kidney Diseasemembranous nephropathy (MN)IgA nephropathy (IgAN)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT07241468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07241468.